Literature DB >> 22172786

Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques.

Johanna M U Silvola1, Antti Saraste, Iina Laitinen, Nina Savisto, V Jukka O Laine, Suvi E Heinonen, Seppo Ylä-Herttuala, Pekka Saukko, Pirjo Nuutila, Anne Roivainen, Juhani Knuuti.   

Abstract

OBJECTIVES: This study investigated the effects of age, duration of a high-fat diet, and type 2 diabetes on atherosclerotic plaque development and uptake of (18)F-fluorodeoxyglucose ((18)F-FDG) in 2 mouse models.
BACKGROUND: The animal's age and start time and duration of a high-fat diet have effects on plaque composition in atherosclerotic mice.
METHODS: The aortas of atherosclerotic low-density lipoprotein receptor deficient mice expressing only apolipoprotein B100 (LDLR(-/-)ApoB(100/100)) and atherosclerotic and diabetic mice overexpressing insulin-like growth factor II (IGF-II/LDLR(-/-)ApoB(100/100)) were investigated at 4, 6, and 12 months of age and older after varying durations of high-fat diet. C57BL/6N mice on normal chow served as controls. Plaque size (intima-to-media ratio), macrophage density (Mac-3 staining), and plaque uptake of (18)F-FDG were studied by means of in vivo positron emission tomography/computed tomography by ex vivo autoradiography and by histological and immunohistochemical methods.
RESULTS: From the ages of 4 to 6 months and 12 months and older, the plaque size increased and the macrophage density decreased. Compared with the controls, the in vivo imaging showed increased aortic (18)F-FDG uptake at 4 and 6 months, but not at 12 months and older. Autoradiography showed focal (18)F-FDG uptake in plaques at all time points (average plaque-to-normal vessel wall ratio: 2.4 ± 0.4, p < 0.001) with the highest uptake in plaques with high macrophage density. There were no differences in the plaque size, macrophage density, or uptake of (18)F-FDG between LDLR(-/-)ApoB(100/100) and IGF-II/LDLR(-/-)ApoB(100/100) mice at any time point.
CONCLUSIONS: The 6-month-old LDLR(-/-)ApoB(100/100) and IGF-II/LDLR(-/-)ApoB(100/100) mice demonstrated highly inflamed, large, and extensive atherosclerotic plaques after 4 months of a high-fat diet, presenting a suitable model for studying the imaging of atherosclerotic plaque inflammation with (18)F-FDG. The presence of type 2 diabetes did not confound evaluation of plaque inflammation with (18)F-FDG.
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172786     DOI: 10.1016/j.jcmg.2011.07.009

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  24 in total

1.  Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques.

Authors:  Petteri Rinne; Sanna Hellberg; Max Kiugel; Jenni Virta; Xiang-Guo Li; Meeri Käkelä; Kerttuli Helariutta; Pauliina Luoto; Heidi Liljenbäck; Harri Hakovirta; Maria Gardberg; Anu J Airaksinen; Juhani Knuuti; Antti Saraste; Anne Roivainen
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

Review 2.  Molecular targets in aortic aneurysm for establishing novel management paradigms.

Authors:  Chengkai Hu; Kai Zhu; Jun Li; Chunsheng Wang; Lao Lai
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

3.  Positron Emission Tomography in Atherosclerosis Research.

Authors:  Anne Roivainen; Mia Ståhle; Antti Saraste
Journal:  Methods Mol Biol       Date:  2022

4.  Identification of inflamed atherosclerotic lesions in vivo using PET-CT.

Authors:  Mateja Kaja Jezovnik; Nina Zidar; Luka Lezaic; Borut Gersak; Pavel Poredos
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

Review 5.  Future imaging of atherosclerosis: molecular imaging of coronary atherosclerosis with (18)F positron emission tomography.

Authors:  Daniel J Scherer; Peter J Psaltis
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

Review 6.  Current and Emerging Preclinical Approaches for Imaging-Based Characterization of Atherosclerosis.

Authors:  Jonathan Vigne; James Thackeray; Jeroen Essers; Marcus Makowski; Zoreh Varasteh; Adelina Curaj; Angelos Karlas; Emmanuel Canet-Soulas; Willem Mulder; Fabian Kiessling; Michael Schäfers; René Botnar; Moritz Wildgruber; Fabien Hyafil
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

7.  18-kDa translocator protein ligand 18F-FEMPA: Biodistribution and uptake into atherosclerotic plaques in mice.

Authors:  Sanna Hellberg; Johanna M U Silvola; Max Kiugel; Heidi Liljenbäck; Nina Savisto; Xiang-Guo Li; Andrea Thiele; Lutz Lehmann; Tobias Heinrich; Sonja Vollmer; Harri Hakovirta; V Jukka O Laine; Seppo Ylä-Herttuala; Juhani Knuuti; Anne Roivainen; Antti Saraste
Journal:  J Nucl Cardiol       Date:  2016-05-25       Impact factor: 5.952

8.  Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals.

Authors:  Tobias Borchert; Laura Beitar; Laura B N Langer; Andras Polyak; Hans-Jürgen Wester; Tobias L Ross; Denise Hilfiker-Kleiner; Frank M Bengel; James T Thackeray
Journal:  J Nucl Cardiol       Date:  2019-10-28       Impact factor: 5.952

Review 9.  Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative.

Authors:  Maria de Fátima Brito; Carla Torre; Beatriz Silva-Lima
Journal:  Front Med (Lausanne)       Date:  2021-07-06

10.  Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Rasmus S Ripa; Emilie H Zobel; Bernt J von Scholten; Jacob K Jensen; Tina Binderup; Lars J Diaz; Viktor R Curovic; Tine W Hansen; Peter Rossing; Andreas Kjaer
Journal:  Circ Cardiovasc Imaging       Date:  2021-06-30       Impact factor: 7.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.